The Hutch Inks Deal with Korean Firm NSB Postech to Test Antibody Arrays | GenomeWeb
The Fred Hutchinson Cancer Research Center and Korean firm NSB Postech will be working together to use NSB’s technology with the goal of building antibody microarrays for proteomics research.
 
Announced last week, the deal represents Fred Hutchinson’s first collaboration in the antibody microarray field, which while gaining traction in proteomics for biomarker research work, still remains something of a supporting technology.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.